In Brief: Genetics Institute/Johns Hopkins
This article was originally published in The Gray Sheet
Executive Summary
Genetics Institute/Johns Hopkins: Form Metamorphix, Inc. to develop and commercialize transforming growth factor-beta (TGF~) genes, which are involved in cell growth and differentiation. GI, a unit of American Home Products, will contribute $3.6 mil. in exchange for 58% of the new company. GI is conducting pilot clinical trials on one type of TGF~ gene it discovered, bone morphogenic proteins, for treating tibia and maxillofacial bone fractures, and for use in spinal reconstruction. The latter trial is part of a four-year, $50 mil. collaboration with Sofamor Danek announced earlier this year ("The Gray Sheet" Feb. 20, I&W-2)...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.